Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
CANbridge Announces NDA Acceptance of CAN108 (邁芮倍®/LIVMARLI®) for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis (PFIC) by China's National Medical Products Administration 2023-10-17 08:00
CANbridge Announces Full Enrollment Reached in the Core Part of The CAN103 Phase 2 Trial for Gaucher Disease in China 2023-10-16 13:38
CANbridge Announces Marketing Approval of CAN108 (/LIVMARLI®) in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome (ALGS) 2023-10-09 08:00
CANbridge to Participate in Two Investor Conferences in September 2023-09-06 16:06
CANbridge Announces Interim Financial Results and Corporate Updates for the Six Months Ended June 30, 2023 2023-08-31 15:15
Qiming's Portfolio Company CANbridge Pharmaceuticals Lists on Main Board of HKEx 2021-12-10 15:15
1